Your Drug Works. Your Model Is Lying.
Preclinical success on artificial models isn't success—it's a delayed failure. We provide the biological truth needed to make confident go/no-go decisions.
How We Solve Your Specific Problem
De-risking Clinical Translation
The Problem: Compounds that look effective in conventional models fail in Phase II because those models don't reflect the biological complexity of a real tumor. Our Solution: We screen your compound across a diverse panel of patient-derived ALI-PDO™ models, providing a statistically robust prediction of clinical response. Our 84.43% clinical outcome prediction rate means you enter the clinic with confidence, not hope. Typical Use Case: A global pharma partner brought us 12 lead compounds from a KRAS-mutant NSCLC program. We screened across 80 patient models in 6 weeks, identifying the top 3 candidates with the highest predicted response rates and a novel biomarker signature for patient selection.